Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus ...
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing gene therapies for severe inherited diseases affecting the central nervous system. The company was founded in 2019 and is headquartered at Pegasus Park in Dallas, Texas. Its technology approach centers on adeno-associated virus, or ...Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing gene therapies for severe inherited diseases affecting the central nervous system. The company was founded in 2019 and is headquartered at Pegasus Park in Dallas, Texas. Its technology approach centers on adeno-associated virus, or AAV, vectors, which are engineered delivery vehicles intended to transport therapeutic genetic material into target cells. The objective is to address the underlying genetic cause of serious monogenic disorders rather than merely manage symptoms.
Taysha's most important disclosed program is TSHA-102, an investigational gene therapy for Rett syndrome, a rare neurodevelopmental disorder commonly associated with mutations in the MECP2 gene. Rett syndrome is characterized by developmental regression, impaired communication, motor dysfunction, and other neurological complications. The program is intended to restore or supplement functional genetic activity through an AAV-based approach. Because TSHA-102 remains investigational, its safety, efficacy, durability, dosing, and regulatory prospects depend on clinical-trial results and review by health authorities.
The company has also disclosed programs and research activities involving disorders such as giant axonal neuropathy, CLN1 disease, SLC13A5 deficiency, and GM2 gangliosidosis. Earlier pipeline descriptions included TSHA-120, TSHA-121, TSHA-118, TSHA-105, and TSHA-101. However, public reporting indicates that Taysha has narrowed its portfolio and that its current investment thesis is increasingly concentrated on TSHA-102. Pipeline status can change as clinical, regulatory, financing, and strategic decisions evolve.
Taysha was formed with a close relationship to The University of Texas Southwestern Medical Center, supporting access to scientific expertise, disease biology, vector technology, and translational research. The company has also built capabilities related to gene-therapy development and manufacturing, although manufacturing scale, quality control, supply-chain execution, and cost of goods remain important considerations for any potential commercial product. AAV manufacturing can require specialized facilities, expensive raw materials, rigorous testing, and complex release procedures. Commercial costs may also be affected by patient identification, treatment-center infrastructure, logistics, and long-term follow-up requirements.
Sean P. Nolan serves as chairman of the board and chief executive officer; he became CEO in 2022 after previously serving in senior biopharmaceutical leadership roles. The supplied company data lists approximately 99 full-time employees, placing Taysha in the 0-100 employee category. As a development-stage biotechnology company, Taysha has historically operated with significant research, development, regulatory, clinical, and administrative expenses and has not generated material product revenue. The supplied trailing data shows negative operating margins, negative net income, and negative free cash flow, alongside a strong current ratio and substantial cash relative to near-term obligations. Consequently, liquidity, cash burn, financing requirements, dilution risk, clinical results, regulatory milestones, and partnership opportunities are central considerations for shareholders. Taysha's stated long-term aspiration is to develop transformative treatments for patients with severe genetic neurological diseases, but commercial success depends on demonstrating meaningful benefit, obtaining regulatory approval, manufacturing reliably, and securing reimbursement.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$9.8M
+17.3%
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-109.0M
-22.1%
-10.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
0.0%
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-1130.6%
-3.0%
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-1115.3%
-4.1%
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-93.8M
-15.0%
+7.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-960.1%
+2.0%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
7.4%
-91.7%
+71.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
12.23x
+125.6%
+26.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Hello, and welcome to the Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Hayleigh Collins.
Hayleigh Collins: Thank you. Good afternoon, and welcome to Taysha's second quarter 2026 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer, Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients we seek to treat. Our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory submissions, timing or outcomes of communications with the FDA on the regulatory pathway for TSHA-102, the potential for product candidate to receive regulatory approval from the FDA or equivalent foreign regulatory agencies. Our ability to realize the benefits of breakthrough therapy designations for TSHA-102, our ability to drive long-term value for stockholders, and the market opportunity for our programs. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway, and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. For a list and description of the risks and uncertainties that we face, please see the reports we filed with the SEC, including our annual report on Form 10-K for the full year ended December 31, 2025, that we filed on March 19, 2026. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 11, 2026. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, …
